PHOENICIA BIOSCIENCES, INC.

Company Information

Company Name
PHOENICIA BIOSCIENCES, INC.
Address
45 Beaver Rd
WESTON, MA, 02493-1017
Phone
n/a
URL
n/a
DUNS
808428689
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
Y

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$288,895.00
1
STTR Phase I
$1,636,697.00
5
STTR Phase II
$999,992.00
1
Chart code to be here

Award List

  1. Development of an Oncogene-Targeted Therapeutic

    Amount: $271,227.00

    DESCRIPTION (provided by applicant): The concept of targeting cancer therapeutics towards specific mutations or abnormalities in tumor cells which are not found in normal tissues has the potential adv ...

    STTR Phase I 2009 Department of Health and Human Services
  2. Virus-Targeted Therapy for Malignancies

    Amount: $288,895.00

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human malignancies for which there are presently few effective treatments. Lymphoid malignancies caused by ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. in vivo Studies of Clinical Stage Globin Modulators

    Amount: $304,344.00

    DESCRIPTION (provided by applicant): Inherited disorders which decrease production or alter structure of the 2-chain of hemoglobin A (2-thalassemias or sickle cell disease) are among the most common m ...

    STTR Phase I 2011 Department of Health and Human Services
  4. Oral Agents to Stimulate Neutrophil Production

    Amount: $350,566.00

    DESCRIPTION (provided by applicant): Phoenicia Biosciences, Inc. scientists have discovered a small family of low MW compounds (short-chain fatty acid derivatives (SCFADs) - designated Hemokines ) th ...

    STTR Phase I 2010 Department of Health and Human Services
  5. Next Generation Therapeutics for Hemoglobinopathies

    Amount: $491,254.00

    DESCRIPTION (provided by applicant): Sickle cell disease and 2-thalassemias are mankind's most common hereditary monogenic diseases, comprise a major global health burden, and cost the US healthc ...

    STTR Phase I 2012 Department of Health and Human Services
  6. Topical Therapeutic to Promote Healing of Chronic Wounds

    Amount: $219,306.00

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is ...

    STTR Phase I 2013 Department of Health and Human Services
  7. Development of a clinical hemoglobin modulator

    Amount: $999,992.00

    DESCRIPTION (provided by applicant): The -thalassemias and sickle cell disease are serious genetic blood diseases, which are WHO- designated as a growing global health burden. The disorders decrease ...

    STTR Phase II 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government